BioCryst to Present at the J.P. Morgan Healthcare Conference
January 04 2017 - 06:45AM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that
executives from BioCryst are scheduled to present and provide a
corporate summary and update regarding the Company’s development
programs at the 35th annual J.P. Morgan Healthcare Conference in
San Francisco on Wednesday, January 11, 2017 at 1:30 p.m. Pacific
Time.
BioCryst’s conference presentation slides will
be available for downloading from the BioCryst website events page
at noon on Sunday, January 8th Pacific Time at the link below:
http://investor.shareholder.com/biocryst/events.cfm. The live audio
webcast and a replay of the presentation will also be available at
the link above.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved
in rare diseases. BioCryst currently has several ongoing
development programs: BCX7353 and second generation oral inhibitors
of plasma kallikrein for hereditary angioedema, and galidesivir, a
broad spectrum viral RNA polymerase inhibitor that is a potential
treatment for filoviruses. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, is
BioCryst’s first approved product and is currently marketed in the
U.S., Japan, Taiwan and Korea. Post-marketing commitment
development activities are ongoing, as well as activities to
support regulatory approvals in other territories. For more
information, please visit the Company's website at
www.BioCryst.com.
This press release contains forward-looking
statements, including statements regarding future results and
achievements. These statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performances or achievements expressed or implied
by the forward-looking statements. Please refer to the documents
BioCryst files periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2023 to Mar 2024